Stifel on Immunic Inc. (IMUX): 'Overall, we see a number of potential avenues for differentiation for VidoCa'
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $25.00 price target on Immunic Inc. (NASDAQ: IMUX).The analyst comments "Today ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
